Trial Profile
A Multicenter, Double-blind, Placebo-controlled, Randomized, Parallel-group Phase 3 Study to Evaluate the Safety and Efficacy of Masitinib in Patients With Mild to Moderate Alzheimer's Disease
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 01 Oct 2023
Price :
$35
*
At a glance
- Drugs Masitinib (Primary) ; Donepezil; Galantamine; Memantine; Rivastigmine
- Indications Alzheimer's disease
- Focus Registrational; Therapeutic Use
- Sponsors AB Science
- 30 Jul 2021 Results presented at the Alzheimer's Association International Conference 2021
- 29 Jul 2021 According to an AB Science media release, the full abstract will be published in a supplement of Alzheimer's & Dementia (the journal of the Alzheimer's Association).
- 29 Jul 2021 According to an AB Science media release, results from this study have been presented at the annual Alzheimer's Association International Conference (AAIC) (July 26-30, 2021).